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Treatment of central nervous system (CNS) diseases is limited by the blood-brain 
barrier (BBB), a selective vascular interface restricting passage of most molecules from 
blood into brain.  Specific transport systems have evolved allowing circulating polar 
molecules to cross the BBB and gain access to the brain parenchyma.  However, to date, few 
ligands exploiting such systems have proven clinically viable in the setting of CNS diseases.   
 We reasoned that combinatorial phage-display screenings in vivo would yield 
peptides capable of crossing the BBB and allow for the development of ligand-directed 
targeting strategies of the brain.  Here we show the identification of a peptide mediating 
systemic targeting to the normal brain and to an orthotopic human glioma model.  We 
demonstrate that this peptide functionally mimics iron through an allosteric mechanism and 
that a non-canonical association of (i) transferrin, (ii) the iron-mimic ligand motif, and (iii) 
transferrin receptor mediates binding and transport of particles across the BBB.  We also 
show that in orthotopic human glioma xenografts, a combination of transferrin receptor over-
expression plus extended vascular permeability and ligand retention result in remarkable 
brain tumor targeting.   Moreover, such tumor targeting attributes enables Herpes simplex 
 vii 
virus thymidine kinase-mediated gene therapy of intracranial tumors for molecular genetic 
imaging and suicide gene delivery with ganciclovir.  Finally, we expand our data by 
analyzing a large panel of primary CNS tumors through comprehensive tissue microarrays.  
Together, our approach and results provide a translational avenue for the detection and 
treatment of brain tumors. 
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CHAPTER 1: INTRODUCTION AND REVIEW OF THE LITERATURE  
 Malignant gliomas are the most common primary brain tumor in adults (1).  In the 
United States, nearly 15,000 individuals will be diagnosed with malignant glioma annually 
(1).  The incidence has remained relatively constant over the last decade; however, 
improvements in the sensitivity of diagnostic imaging techniques have lead to a slight 
increase in incidence in certain populations, including the elderly.  While representing a 
relatively small percentage of total cancer diagnoses (~1% of all new cases diagnosed 
annually in the United States), malignant gliomas--comprising anaplastic astrocytomas and 
glioblastomas-- account for a disproportionately high number of deaths from central nervous 
system (CNS) related diseases (1). 
 To date, only ionizing radiation has been documented as a risk factor (2).  Additional 
causal agents have been suggested, but are as of yet inconclusive, including head injuries, 
exposure to electromagnetic fields, or contact with N-Nitroso-N-methylurea containing 
compounds (2).   A small percentage of patients will present with a family history of 
gliomas (~5%), often without an identified genetic link.  Familial gliomas have also been 
linked to certain genetic conditions including Li-Fraumeni syndrome, resulting from 
germline mutations in p53, and Turcot’s syndrome, resulting from mutations in mismatch 
repair genes.   
 Gliomas are classified according to the World Health Organization scale, grades I to IV, 
largely based on histological, genetic, and prognostic characteristics (summarized in Fig. 1) 
(3-5).  The lowest grade gliomas, grade I pilocytic astrocytomas, are considered benign and 
potentially curable with surgical resection.  Grade II gliomas, diffuse astrocytomas, are slow 
progressing lesions that are often incurable due to wide-spread infiltration early in the course
 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Genetic alterations and disease progression in glioblastoma.  The scheme 
depicts the general epidemiology of glioblastoma, and the corresponding molecular and 
genetic aberrations associated with disease initiation and progression.  Reprinted with 
permission, Furnari, F.B. et al., Genes Dev 21:2683-2710 (Reference 3), Copyright © 
2007, Cold Spring Harbor Laboratory Press. 
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of the disease.   With increased anaplasia and cellular proliferation, grade III gliomas or 
anaplastic astrocytomas, are often more aggressive and more rapidly lethal.  Glioblastoma 
(GBM), grade IV glioma, is the most aggressive, invasive, and highest grade glioma marked 
by vascular proliferation or necrosis (pseudopallisading).  GBM is responsible for nearly 
60% of newly diagnosed gliomas and is often separated into two subtypes based on 
differences in molecular, genetic and clinical presentation: (i) primary and (ii) secondary (1).  
Primary glioblastomas often occur in patients at 50 years of age or older and are commonly 
characterized by amplifications in the epidermal growth factor receptor (EGFR) or deletions 
in phosphatase and tensin homologue on chromosome 10 (PTEN) and/or p16.  Secondary 
glioblastomas arise from lower grade gliomas, including grade III anaplastic astrocytomas, 
present in patients less than 45 years old, and often overexpress platelet derived growth 
factor receptor (PDGFR), have mutations in p53, or alterations to the p16 or retinoblastoma 
(Rb) signaling pathways (3, 6). 
 Clinically, patients present with varied symptoms, including progressive headaches, 
seizures, and/or neurological alterations or defects.  A diagnosis of glioblastoma is generally 
suggested by contrast-enhancing lesions from contrast-enhanced magnetic resonance 
imaging (MRI) or computed tomography (CT).  However, definitive diagnosis of GBM 
predominantly remains a pathological assessment, often necessitating invasive tumor 
biopsies.  GBM shares histological features with lower grade gliomas, including increased 
cellularity, nuclear atypia, and neoplastic astrocytes (5, 7).  Yet, microvascular 
hyperproliferation or necrosis (including pseudopallisading) are often considered diagnostic 
features separating GBM from lower grade gliomas.  Despite the known molecular and 
genetic differences between primary and secondary classifications, primary and secondary 
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GBM are pathologically indistinguishable and both respond similarly to standard therapeutic 
regimens.  Of note, emerging genetic studies show promise in improving genetic 
stratifications and classifications (8, 9).   
 The standard of care for newly diagnosed GBM is maximal surgical resection combined 
with adjuvant radiotherapy and chemotherapy with temozolomide (10-12).  Unfortunately, 
despite this aggressive therapeutic regimen, the median survival for patient remains 12-15 
months and local recurrence is a leading cause of eventual mortality.  Recent improvements 
in understanding the molecular and genetic characteristics of GBM have introduced several 
new classes of investigational agents, including receptor tyrosine kinase inhibitors (i.e., 
Erlotinib and Cetuximab), small molecule inhibitors of intracellular signaling pathways (i.e., 
Tamoxifen and Sirolimus), and antiangiogenic therapies (i.e., Bevacizumab) (3, 10, 13).  
However, the practical use of such newer therapeutic strategies for the treatment of brain 
tumors is often hampered by ineffective delivery of agents into the brain.  Complicated by 
the presence of the highly specialized blood-brain barrier (BBB) and variability in 
microvascular functions at the blood-tumor interface, systemically circulated agents 
potentially meet highly restrictive barriers.  As a result, many current drugs treating CNS 
disorders are created as highly lipophilic agents, leading to increased systemic toxicity and a 
lowering of the therapeutic index (14, 15).  A clear need exists for improved therapies for 
the management and treatment of GBM.  
 
CHAPTER 1.1: THE BLOOD-BRAIN BARRIER 
 Paul Ehrlich first suggested the existence of the BBB through experiments evaluating the 
tissue distribution of dye following intravenous administration and the lack of uptake by the 
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brain (16).   Edwin Goldmann subsequently confirmed this hypothesis through a series of 
experiments generating the concept of an impermeable barrier between the systemic 
circulation and the brain (17).  Further study of this phenomenon identified the brain 
microvascular cells and corresponding intracellular junctions as the functional barrier 
limiting passage (18).  The current concept of the BBB has been refined to support a 
complex yet coordinated functional unit, termed the neurovascular unit, comprised of brain 
endothelial cells, astrocytes, perivascular neurons, and pericytes (19-21).  Moreover, it is 
now known that the BBB is highly regulated and selective, not impermeable, separating both 
the brain parenchyma and spinal cord from circulating blood to maintain CNS homeostasis.  
The BBB physically exists at the level of brain capillaries; however, certain regions of the 
brain have less strict or absent barrier function, defined as the circumventricular organs 
(CVOs) (22). The CVOs are closely apposed to the third and fourth ventricles and include 
the area postrema, neurohypophysis, pineal gland, subfornical organ and the median 
eminence.  Acting as sensory or secretory organs, the CVOs utilize extracellular transport 
systems and the presence of fenestrate (pores) within the endothelial lining - allowing free 
passage between blood and brain - to monitor the composition of the blood or to secrete 
hormones into the systemic circulation.  Similarly, capillaries supplying the choroid plexus, 
which secretes cerebrospinal fluid, are fenestrated.  Yet, it is the presence of tight junctions 
between cells within the epithelium that creates a barrier separating the cerebrospinal fluid 
from the brain. 
 Development of the BBB begins during embryogenesis as angiogenic blood vessels 
invade the neuroectoderm and anastomose to form the early brain microcirculation (23).  
The timing and arrangement of angiogenic sprouting is precisely regulated by a number of 
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interactions between growth factors and cognate receptors, the most well-studied of which is 
vascular endothelial growth factor (VEGF) and the VEGF receptor.  Studies have 
demonstrated that a lack of VEGF is embryonically lethal, and the localization and diffusion 
of VEGF dictates the spatial patterning of the vascular network in development (24).  The 
premature vascular network is largely considered abnormal, with prominent structural 
irregularities, large caliber blood vessels, and endothelial cell fenestrae (25).  Such features 
are thought to render the brain capillaries permeable to small molecules, although the extent 
to which the vasculature is leaky during fetal development remains controversial.  The early 
microvascular system also displays molecular profiles differentiating it from the BBB in the 
adult.  Indeed, the presence of the glucose transporter-1 (Glut-1), the Src family tyrosine 
kinase lyn, P-glycoprotein, and MECA 32 antigen have all proven to serve as early markers 
of the developing vascular network (26). 
 The process of blood vessel maturation, and “barriergenesis,” is gradual and induced by 
external stimuli (27).  The putative candidate(s) cell types eliciting molecular changes in the 
endothelium, including astrocytes, pericytes, extracellular matrix, and even neural 
progenitor cells, reside in close proximity to the brain microvessels.  Yet, the exact cell type 
and molecular mediators driving barrier formation remains to be determined.  Due to their 
close positioning near capillaries, and the timecourse of cell migration and differentiation, 
astrocytes have been implicated as potential sources of inductive signals (28).  However, as 
astrocytes are also present in CVOs, this lends support to the notion that while functionally 
necessary, they do not drive BBB establishment.  Pericytes, or mural cells, are required for 
the maturation and stabilization of the microcirculation and are encapsulated by a shared 
basement membrane with endothelial cells (29).  Long cellular processes remain in intimate 
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contact with the endothelium and have been functionally implicated in the regulation of 
blood flow, particularly in the cerebrum (30).  During developmental angiogenesis, pericyte 
migration occurs before microvessel sprouting and guides developing neovessels.  A number 
of molecules acting on the endothelium have been identified, including angiopoietin-1 and 
PDGF-BB (29, 31).  These factors have been identified as crucial molecules in establishing 
endothelial cell-pericyte interactions and function; however, definitive determination of 
BBB induction remains elusive.  Similarly, while adhesion molecules, including cadherins 
and integrins, maintain cell-cell and cell-matrix interactions to ensure proper cellular 
function, it remains an open question as to whether molecules such as N-cadherin or αvß8 
contribute to induce BBB establishment.  
 Although each component of the neurovascular unit contributes to the function of the 
BBB, capillary endothelial cells and associated tight junctions largely regulate permeability 
from blood to the CNS (18).  The endothelial lining forming the BBB is a single layer of 
cells bound by a complex junctional network including tight, adherens, and gap junctions; 
the contribution of gap junctions to the BBB remains controversial.  Both tight junctions and 
adherens junctions are marked by specific arrangements of protein components and 
accessory intracellular adapter proteins linked to the actin cytoskeleton.  These all contribute 
to a high electrical resistance and formation of a physical impermeable barrier (21).  Under 
normal conditions, the BBB restricts passage of plasma constituents, including circulating 
polar molecules, unless specific transport systems present on the endothelium are used (32).  
The general classes of known transport mechanisms allowing transcellular passage of 
necessary macromolecules and nutrients into the brain include:  (i) lipid-mediated transport 
of lipid-soluble small molecules with molecular weights less than 400 Da, (ii) carrier-
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mediated transport, (iii) receptor-mediated transport, (iv) ion transport, and (v) absorptive 
endocytosis (21).   A number of carrier-mediated transporters at the BBB have been 
identified, including the monocarboxylate transporter 1, L1 amino acid transporter, and 
CNT2 adenosine transporter.  One of the most well studied carrier-mediated transport 
systems is GLUT1, a brain endothelial specific glucose transporter (33).  GLUT1 expression 
is differentially regulated, with a greater number of receptors present at the abluminal 
membrane than facing the lumen, which support a functional regulation of glucose between 
the blood and brain.  Moreover, mutations in GLUT1 lead to seizures in infancy, 
developmental delay, and potential microenchephaly, a condition termed GLUT1 deficiency 
syndrome (33).  Circulating molecules such as insulin, transferrin and neuropeptides are 
unable to use small molecule carrier systems and require cell surface receptor-mediated 
transport for transcellular movement.  Receptor-mediated internalization and transcytosis are 
highly regulated, often with receptor turnover rates much slower than in other anatomical 
locations, and this may potentially act as a mechanism to limit passage into the brain (34).  
To maintain interstitial fluid balance and pH, the sodium pump, sodium-potassium-chloride 
cotransporter, and several exchange transporters exist to regulate ion concentrations between 
the blood and brain and also demonstrate differential expression on the endothelial 
membrane (35).   
 Disruption of the BBB occurs in a number of disease states, including inflammatory 
disorders and cancer, permitting unregulated passage from the blood into the brain (21).  
The resultant influx of proinflammatory molecules and immune cells exacerbates the BBB 
breakdown as well as induces a secondary immune response by the resident CNS microglia.  
One of the early steps in BBB disruption is an increase in vascular permeability 
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accompanied by loosening of interactions between endothelial cells, particularly at the level 
of the tight junctions (18).  Overexpression of HIF-1α and VEGF have been causally linked 
to BBB alterations, and it was recently shown that high levels of VEGF disrupts the BBB 
through downregulation of claudin-5 and occludin expression (36).  Indeed, several 
components of tight and adherens junctions have been implicated as either lost or altered in 
BBB disruption, including claudin-5, occludin, ZO-1, VE-cadherin, and ß-catenin (18).  
Ultimately, the unpredictable barrier function and vascular blood flow associated with BBB 
disruption presents a challenge towards delivery of agents to therapeutic levels.  As such, the 
temporal dynamics and relative contribution of BBB disruption to disease progression 
particularly in cancer and its impact on drug delivery remains an active area of basic and 
clinical research. 
 
CHAPTER 1.1.1: TRANSFERRIN AND TRANSFERRIN RECEPTOR 
 Iron is an essential multi-functional element, acting as an enzymatic cofactor in 
diverse physiological processes or as a coordinating compound in macromolecules.  The 
levels of iron within the body are narrowly regulated, primarily at the process of iron uptake, 
as loss of iron is minimal under normal conditions (37).  Iron exists in two forms, either in a 
ferrous (Fe2+) or ferric (Fe3+) state.  Despite such critical involvement in normal cellular 
function, free iron, particularly ferric iron, can lead to accumulation of insoluble compounds 
or to the generation of hazardous free radicals.  To circumvent the toxic potential of iron, 
mechanisms including circulating protein carriers and intracellular storage molecules have 
evolved to limit the levels of free iron.  One such family of iron transport proteins, that 
includes transferrin and the multi-functional protein lactoferrin, binds ferric iron and 
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distributes it through the systemic circulation (38).  In fact, the crucial role of transferrin in 
maintaining homeostasis is supported by clinical observations from individuals lacking 
transferrin who suffer from growth retardation, anemia, manifestations of iron overload, and 
increased risk of infection (39).  
 Transferrin (Tf) is a ~80kD monomeric glycoprotein secreted largely from the 
hepatocytes, and to a lesser extent by Sertoli cells, ependymal cells, oligodendroglia, and 
several cancer cells (39, 40).  The single polypeptide is functionally split into two 
homologous halves, termed the C- and N-lobes, connected by a small linker sequence.  Each 
lobe is sub-divided into two domain structures containing a cleft for iron ion binding.  As 
such, the iron free Tf (apo-transferrin; apo-Tf) is capable of binding either a single iron 
molecule (monoferric Tf) or two iron molecules (holo-transferrin; holo-Tf) (41).  Binding, 
and eventual release of iron, is largely influenced by several factors including micro-
environmental pH and relative ionic concentrations.  In serum, the concentration of Tf is 
very stable, and it has a half-life of ~8-10 days, which affords an estimated 100 cycles of 
iron transport into cells (42).  Clinically, iron saturation is a diagnostic measure to assess 
iron levels in the body, and typically Tf levels of holo-Tf represent 10-30% of the 
circulating pool (40).   
 The transferrin receptor (CD71; TfR) is a cell surface, monomeric glycoprotein 
predominantly found as a disulfide linked homodimer (43-45).  With a short, single-pass 
transmembrane domain and a large extracellular domain, absence of this essential type 2 
transmembrane protein causes embryonic lethality due to impairments in red cell and 
neuronal development.  TfR is expressed at low levels in virtually all normal cells and is 
highly expressed in actively dividing cells, including cancer cells (45).  TfR is robustly 
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expressed on the endothelium in the brain and has been the subject of intense study as an 
intrinsic mechanism of blood-brain barrier transport (46, 47).  Expression is regulated post-
transcriptionally by iron regulatory proteins interacting with iron response elements in the 3’ 
untranslated region of the TfR mRNA(48).  In addition, another homologous family member 
of the transferrin receptor family, TfR2, was described with regulation and expression that 
greatly differs from TfR (49).  The expression of TfR2 is controlled by the cell cycle and not 
regulated by iron levels, and it has a much narrower tissue distribution profile, almost 
exclusively expressed in hepatocytes (50).  
 Typically, dietary iron crosses the epithelial lining of the duodenum via the divalent 
metal transporter 1 (DMT1) and into the portal circulation via ferroportin (48).  Once in the 
circulation, ferric iron is rapidly sequestered by Tf (apo-Tf) and transported to target cells.  
Two molecules of holo-Tf bind the TfR homodimer located in clathrin-coated pits, and the 
complex is internalized by receptor mediated endocytosis.  The endocytosed vesicle is 
transported to the endosome where the low intra-vescicular pH results in a conformational 
change in Tf, releasing iron.  Iron is transported out of the endosome by the DMT1 and TfR 
is recycled back to the cell surface to release the iron-free apo-Tf.  The entire cellular uptake 
process is reviewed in Figure 2. 
  
CHAPTER 1.2: PHAGE DISPLAY 
 George Smith first described phage display as a methodology to probe binding sites of 
isolated antibodies (51).  This work demonstrated that filamentous bacteriophage (phage) 
particles could be engineered to express protein fusion fragments inserted into surface 
capsid proteins (Fig. 3) (52).  Using a fragment of the endonuclease EcoRI as a proof-of-
 12 
      
    
Figure 2.  Transferrin receptor internalization and recycling pathway.  Scheme 
depicts the typical receptor binding and cell interalization of iron-loaded transferrin.  
Image courtesy of Mr. David Bier. 
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Figure 3. General filamentous phage display vector structure. (A) Diagram of the 
coat protein distribution for the pVIII major and pIII, pVI, pVII, and pXI minor coat 
proteins.  (B) Scheme of pIII domain arrangment and location of pIII displayed peptides.  
Reprinted with permission, Ozawa, M.G. et al. In CNS Cancer: Models, Markers, 
Prognostic factors, and Therapeutic approaches.  Ed. E.G. Van Meir (Reference 52).  
Copyright © 2009, Humana Press, New York. 
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concept, the resultant EcoRI-expressing phage remained biologically active, infecting host 
bacteria, while also binding to antibodies recognizing EcoRI (51).  Sequential rounds of 
affinity selection confirmed binding specificity to the cognate antibody of EcoRI-displaying 
phage compared to wild-type phage.  Subsequently, several independent groups expanded 
upon this initial work to generate libraries of phage clones displaying random peptide 
sequences.  These combinatorial peptide libraries were then used as screening tools to 
identify residues mediating binding to antibody antigenic sites (53, 54).  The method, termed 
“panning,” employed serial rounds of selection whereby phage adherence, recovery, and 
amplification permitted the identification of phage preferentially binding to a target.  DNA 
sequence analysis of phage clones determined the amino acid sequence mediating binding, 
and in a larger context, the phage peptide sequences could then be compared through 
biochemical and bioinformatic-based assays to determine potential native proteins the phage 
sequence could functionally mimic.  The approach has since been applied in the context of 
various diseases, such as cancer, as a means to identify cell surface antigens eliciting 
humoral responses in cancer patients.  Indeed, Mintz et al., through interrogation of 
circulating antibodies in a prostate cancer patient, identified glucose regulated protein-78 as 
a tumor antigen (55).  Similarly, Vidal et al., identified and characterized peptides 
mimicking heat shock protein 70 as being recognized by antibodies present in ascities fluid 
of ovarian cancer patients (56).  
 Through recognition of the diverse experimental conditions in which protein-protein 
interactions could be explored, a large number of groups expanded the technical and 
biological applications of phage display to settings in vitro and in cellulo.  Screenings on 
isolated molecules have enabled identification of native protein ligands for receptors.  For 
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example, phage display elucidated that the adhesion molecule beta-neurexin binds the 
Staphylococcus aureus microbial surface components recognizing adhesive matrix molecule 
(MSCRAMM) SdrC, and mapped key sites of interaction such as the tetratricopeptide repeat 
of the mitochondrial fission protein hFis1 (57, 58).  Moreover, the identified peptides often 
have inherent activity, as studies have described active peptide inhibitors of trypsin 
isoenzymes and as well as growth factor receptor antagonists (59, 60).  Similarly, profiling 
of cultured cells has afforded the opportunity to identify specific cell binding peptides in 
leukemia, molecular signatures for tumor types of the NCI-60 cancer cell panel, as well as 
differentially expressed receptors through comparative analysis of stimulated versus 
quiescent cells (61-63).  These studies were enabled by a cell separation strategy coined 
biopanning and rapid analysis of serial interacting ligands, or BRASIL (61).  In the proof-of-
concept study, peptides specifically binding to VEGF stimulated endothelial cells were 
isolated and characterized following centrifugation through a density gradient.  One peptide, 
CPQPRPLC, functionally mimicked VEGF and demonstrated binding specificity for both 
VEGFR-1 and Neuropilin-1.  Subsequent studies identified the key residues mediating 
CPQPRPLC binding to VEGFRs and lead to the derivation of a small, retro-inverted peptide 
possessing anti-angiogenic properties (64, 65). 
  Concurrent to the rapid success of combinatorial phage display screenings in vitro, 
investigators explored the potential for identifying protein-protein interactions in vivo.  The 
experimental approach in principle paralleled in vitro screenings, where a combinatorial 
library was intravenously administered and allowed to interact with the tissue of interest 
through the circulation; bound phage were recovered from tissues, amplified, and used for 
subsequent screenings to enrich for selective binding peptides.  Pasqualini and Ruoslahti 
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pioneered the initial study in vivo demonstrating a unique distribution of peptides to the 
kidney and brain (66).  In a subsequent study, phage display screenings on tumor xenografts 
were performed with the goal of identifying vascular markers of tumor endothelial cells.  
The tri-peptide motifs Arg-Gly-Asp (RGD) and Asn-Gly-Arg (NGR) were confirmed to 
mediate selective accumulation in tumors following systemic administration (67).  Further 
characterization of the targeting motifs identified the cell surface receptor for RGD as the 
αvß3 and αvß5 integrins and the protease aminopeptidase N as the receptor for NGR.  
Moreover, the authors demonstrated that linking the motifs to chemotherapeutics resulted in 
robust reductions of tumor burden in pre-clinical tumor models.  Thus, these data supported 
the emerging concept of vascular targeting as a novel paradigm to develop therapeutic or 
diagnostic agents that are more selective and efficacious.  
 More recently, to permit a more direct translation of identified targeting peptides to 
patients, several investigators have adapted phage display screenings to patients.  In the first 
study in a human, Arap et al. administered a combinatorial phage display library to a 
terminal wean cancer patient and recovered several organ biopsies for analysis (68, 69).  
Focusing on the prostate, the group identified a peptide that bore primary sequence 
similarity to the human cytokine interlukin-11 (IL-11).  Subsequent comparative study of the 
peptide, cognate protein, and native receptor revealed a new site of interaction on the 
exposed surface of IL-11 mediating binding to the IL-11 receptor alpha (IL-11Rα) (70).  
Evaluation of the IL-11:IL-11Rα signaling axis in human prostate cancer identified a 
positive correlation between IL-11Rα expression and cancer progression and demonstrated 
that targeting of IL-11Rα with a pro-apoptotic peptide yielded robust cellular apoptosis (71).  
These data led to the development of a novel, vascular-targeted, small molecule drug 
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candidate that is currently enrolling as a Phase I efficacy study.  Supporting this patient-
focused approach, Krag et al., recently reported use of phage display libraries in a cohort of 
cancer patients (72).  The authors performed serial screenings in the same patient and 
identified a non-random distribution of peptides to different tumor types.  Taken together, 
future studies of phage distribution and identification of a human vascular map appears 
imminent. 
 
CHAPTER 1.2.1: AAVP 
 Combinatorial phage display screenings, along with other genomic and proteomic 
methodologies, helped advance the identification of molecular differences between different 
cell and tissue compartments.  Exploitation of such unique characteristics, including 
endothelial cell heterogeneity between organs, enabled strategies for site-specific delivery to 
diseased cells and vascular targeting through the systemic circulation.  These concepts 
naturally garnered much enthusiasm to integrate targeting ligands to other systems for 
improved therapeutic indices.  Indeed, one such area was the field of gene therapy, where 
one of the basic tenets is to deliver modifying genes specifically to diseased cells, thereby 
limiting untoward effects on normal cells.  While the applications for gene delivery have 
greatly expanded beyond simple gene replacement strategies to include use of oncolytic 
viruses as local therapy (73), precise delivery to target cells remains most paramount (74). 
Thus, among the numerous critical factors and fundamental challenges for successful gene 
therapy approaches, delivery specificity, adequate cell transduction, and length of transgene 
expression remain the most elusive. 
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 Mammalian viruses, such as adeno-associated virus (AAV), have an inherent tropism for 
all mammalian cells, high transduction efficiencies, and have been widely used in the field 
of gene therapy (75).  However, this tropism is largely non-specific and previous attempts to 
enhance selective accumulation through manipulation of coat proteins resulted in overall 
lower transduction efficiencies (76).  Thus, it stood to reason that systems that allow for 
ligand-directed targeting of vectors such as AAV could greatly improve cell transduction 
and efficacy of therapeutic regimens.  Hajitou et al., exploited the similarities between 
phage and recombinant AAV to generate a chimeric gene delivery vehicle that possessed 
specific genomic elements from both viruses, coined as AAV-Phage (AAVP) (77).  This 
initial study reported that the chimera preserved the targeting properties afforded by phage-
displayed peptides while also maintaining high in vitro and in vivo transduction rates from 
AAV.  Moreover, this novel reagent readily integrated into the genome and formed 
transgene concatamers, which in combination allowed for prolonged gene expression for up 
to 50 days in vitro. 
 In vivo, AAVP particles engineered to target alpha v integrins readily accumulated in 
pre-clinical tumor models and allowed for delivery of various transgene cassettes, including 
GFP and Herpes simplex virus thymidine kinase (HSVtk); the latter acting both as a 
molecular-genetic imaging tool as well as a gene-directed enzyme prodrug therapy strategy 
(78, 79).  The introduction of the HSV thymidine kinase into cells creates a system whereby 
nucleoside substrates are phosphorylated, preventing export out of the cell (80).  When 
radiolabeled nucleosides are administered, such as the clinically applicable [18F]-FEAU, 
cells expressing HSVtk retain the radioactivity, and this allows for imaging by positron 
emission tomography (PET) and determination of tissue organ and localization.  One week 
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after a single administration of targeted AAVP-HSVtk to tumor bearing animals, localization 
of [18F]-FEAU demonstrated robust and dynamic transgene expression within the tumor 
(77).  Serial evaluation over time within the same animal suggested that targeted AAVP-
HSVtk allowed for monitoring of tumor cell growth and expansion dynamics.  Similarly, 
HSVtk-mediated phosphorylation of the nucleoside analog ganciclovir (GCV), which is 
used clinically to treat cytomegalovirus infections, generates a pro-drug capable of genomic 
integration and eventual cellular apoptosis.  Hajitou et al., utilized this suicide-gene therapy 
approach with targeted AAVP-HSVtk and observed dramatic tumor mass reductions in both 
immunocompromised and immunocompetent animals.  Corresponding PET imaging 
validated the net decrease in tumor volume through comparisons of pre- and post-treatment 
[18F]-FDG, an indicator of metabolic activity and tumor viability, and [18F]-FEAU levels.   
 As the prototype targeted AAVP-HSVtk predominantly localized to the tumor 
vasculature, it was proposed that vascular disruption and resultant hypoxia induced tumor 
cell apoptosis and tumor growth suppression.  However, given the robust therapeutic 
efficacy, it remained plausible that more than one molecular mechanism contributed to the 
overall effect.  Subsequent studies of alpha v integrin-targeted AAVP-HSVtk in vivo 
revealed that (i) endothelial cells highly expressing alpha v integrins were readily transduced 
by the AAVP vector, (ii) tumor cells with low integrin expression had very low transduction 
rates, and (iii) apoptosis following GCV therapy occurred in tumor and endothelial cells 
(81).  Mechanistically, AAVP was shown to elicit a heterotypic bystander effect, as 
endothelial cells transduced with HSVtk were sufficient to induce apoptosis in both 
endothelial and adjacent, non-transduced tumor cells.  Intercellular gap junctions, with 
connexins 43 and 26 playing a critical role, mediated transmission of HSVtk therapy.  
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Ultimately, this heterotypic effect combined with the vascular disruption, among other as yet 
unrecognized mechanisms, contributed to targeted AAVP-HSVtk therapeutic efficacy.  
In support of this initial work, use of targeted AAVP hybrid vectors has expanded 
through generation of vectors carrying additional transgenes and application to other tumor 
models.  For example, investigators recently developed an endothelial cell-targeted AAVP 
vector delivering tumor necrosis factor alpha (TNFα) (82).  While the biological activity of 
TNFα is suggested to be concentration dependent, at high local levels it can function both as 
an anti-tumor and anti-angiogenesis agent.  Thus, specific delivery and generation of TNFα 
within tumors could produce a dramatic anti-tumor effect.  Administration of the targeted 
AAVP-TNFα demonstrated selective delivery to the vascular compartment within the 
tumors and mediated significant tumor reduction compared to controls.  More recently, the 
targeted AAVP-TNFα was applied in the first pre-clinical trial of the Comparative Oncology 
Trials Consortium sponsored by the National Cancer Institute (83).  The resultant data 
successfully identified dose ranges and generated pre-clinical support for potential 
translation to a Phase I study.  Thus, the aggregate of these initial studies with AAVP 
suggest that targeted delivery of transgenes, including the dual-functioning HSVtk gene, is 
highly efficacious and may lead to clinically applicable therapeutic and diagnostic tools.   
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CHAPTER 2: METHODS 
Reagents. The following primary antibodies were used: goat polyclonal anti-TfR (R&D 
Systems); mouse monoclonal anti-TfR (Fisher Scientific); rabbit polyclonal anti-
bacteriophage (Sigma), rat monoclonal anti-CD31 (BD Pharmingen), and rabbit polyclonal 
anti-CD31 (AbCam). Secondary HRP-conjugated anti-rabbit IgG, Cy3-conjugated anti-
rabbit IgG, Cy5-conjugated anti-hamster IgG, and FITC-conjugated anti-rat IgG were 
purchased from Jackson ImmunoResearch Laboratories. Human TfR (> 95% purity) and 
FragELTM were purchased from Calbiochem, and human apo-Tf (> 90% purity) and holo-Tf 
(> 90% purity) from R&D Systems. All synthetic peptides were synthesized and cyclized 
according to our specifications by commercial vendors (AnaSpec or PolyPeptide 
Laboratories). 
 
Cell culture.  U87-MG human glioblastoma cells (ATCC) were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS), penicillin 
(100 units/ml), streptomycin (100 µg/ml), and L-glutamine (2 mM) (84). Rat gliosarcoma 
cells (9L) were obtained from ATCC and rat gliosarcoma cells expressing human TfR (9L 
3.9) were obtained as described (85). Cells were maintained in DMEM supplemented with 
10% FBS and the selection drug geneticin (G418; Gibco). 
 
Animals.  Eight-week-old female nude (nu/nu) mice and Balb/c mice were housed in the 
animal facilities of the University of Texas M. D. Anderson Cancer Center (UTMDACC) in 
Houston, Texas or the Ludwig Institute for Cancer Research at the University of California 
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San Diego (LICR/UCSD) in La Jolla, California. All animal procedures were reviewed and 
approved by the Institutional Animal Care and Use Committees of these institutions. 
 
Orthotopic human glioblastoma xenografts.  We used a guide-screw system (86) to 
implant human glioma cells directly into the mouse brain. In brief, a customized guide screw 
(~2.6 mm long) containing a central channel (~0.5 mm in diameter) was inserted through the 
skulls of female nude mice at a location immediately above the caudate nucleus (~2.5 mm 
lateral, 1 mm anterior to the bregma).  This site is widely used as a reliable location for 
intracranial orthotopic tumor xenografts.  Mice were kept under deep anesthesia throughout 
the procedure. One week after implantation of the guide-screw, animals were re-
anesthetized, and a solution of 5 x 105 human glioma cells in 5 µL phosphate buffered saline 
(PBS; pH 7.4) was injected into the brain with a Hamilton syringe.  The cell suspension was 
administered slowly (5 to 10 min) with the aid of an infusion pump (Harvard Apparatus).  
Following disbursement of the tumor cells, the needle was slowly removed to limit volume 
loss and a stylet was inserted into the screw to close the system and prevent cell leakage.  
Animal body temperature was maintained until full recovery from anesthesia.  In vivo 
homing experiments with targeted and control phage were performed ~12-15 days after 
tumor implantation. 
 
Subcutaneous human glioblastoma xenografts.  Subcutaneous xenografts were 
established following subcutaneous injection of a cell suspension containing 3 x 106 U87-
MG cells into the right flank of nude mice.  Tumor homing experiments were performed 
when palpable subcutaneous tumor xenografts reached 6-8 mm in diameter. 
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Phage display selection and phage homing in vivo. In vivo phage display screening on the 
brain was performed as described (66, 87-89). In brief, a combinatorial phage library 
displaying short cyclic peptides (CX7C; C, cysteine; X, any amino acid) was intravenously 
administered into anesthetized Balb/c mice via the tail vein. Animals received 1010 
transducing units (TU) of the phage library diluted in 200 µl DMEM, and brains were 
collected after 24 h of systemic circulation.  Brains were transferred to 1 ml DMEM 
containing a protease inhibitor cocktail (DMEM-PI; 1 mM 4-(2-Aminoethyl) 
benzenesulfonyl fluoride hydrochloride [AEBSF], 20 µg/ml aprotinin, 10 µg/µl leupeptin, 1 
mM phenylmethylsulfonyl fluoride [PMSF]) and homogenized in a Dounce glass tissue 
grinder.  The homogenate was vortexed for 30 sec and centrifuged at 4,000 rpm for 3 min, 
followed by removal of the supernatant.  This wash step was repeated three times, and after 
the third wash, the pellet was incubated with 1.5 ml of host bacteria (Escherichia coli; 
K91kanR) with an Optical Density at 600 nm (O.D.600) of 2.0 for one hour at room 
temperature (RT).  The admixture was diluted in 10 ml of Luria-Bretani (LB) media 
containing tetracycline (20 µg/ml) and kanamycin (100 µg/ml) for a further 20 min at RT.  
The solution was then plated in multiple aliquots on LB agar plates containing tetracycline 
(40 µg/ml) and kanamycin (100 µg/ml) and incubated at 37oC overnight (O/N).  The 
following day, colonies were (i) counted to determine phage recovery and (ii) picked, 
separately amplified, and pooled for a successive round of screening.  Three serial rounds of 
in vivo selection were performed.  
 For homing of selected phage in vivo, mice were deeply anesthetized and received 1010 
TU of targeted phage or insertless control phage intravenously via the tail vein. After 10 
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min, 30 min, 6 h, or 24 h, mice were systemically perfused through the heart with 10 mL 
DMEM. Brain and control organs were collected and were (i) immersed in PBS for DNA 
extraction, (ii) fixed in 10% neutral buffered formalin (24 h fixation) or (iii) fixed in PBS 
containing 1% paraformaldehyde (PFA; 1 h fixation), followed by O/N incubation in a PBS 
solution containing 30% sucrose at 4°C. 
 
Phage amplification, purification and titration.  The amplification, purification, and 
titration of phage clones have been well described (87, 90).  In brief, individual phage clones 
were incubated with host E. coli bacteria (K91kanR; O.D.600 = 2.0) for 30 min.  The 
admixture was transferred to 500 ml LB containing tetracycline (40 µg/ml) and kanamycin 
(100 µg/ml) then incubated at 37oC for 16-18 h with agitation (250 rpm).  The cultures were 
centrifuged for 15 min at 6,000 rpm and then the phage was precipitated from the 
supernatant by addition of 15% PEG/NaCl and incubation on ice for 4 h.  Cultures were 
centrifuged for 30 min at 10,000 rpm, and the supernatant was discarded.  The phage pellet 
was resuspended in 500 µl PBS and transferred to an eppendorf tube.  The mixture was 
centrifuged at max xg in a tabletop centrifuge to remove residual bacterial contaminants then 
transferred to a new tube.  Quantification of phage particles was accomplished by serial 
dilution of the each phage in PBS followed by infection with host E. coli bacteria.  The 
mixtures were incubated for 30 min followed by duplicate plating of the admixture on LB 
agar plates containing tetracycline (40 µg/ml) and kanamycin (100 µg/ml).  Plates were 
incubated at 37oC O/N and resultant colonies counted.  Phage quantities were expressed as 
TU/µl. 
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Production and titration of phage-based expression vectors. Targeted AAVP chimeric 
vectors were engineered through two intermediate DNA constructs (78).  First, we isolated 
plasmid DNA from overnight host bacterial cultures (E. coli; MC1061) for the fUSE5 and 
fMCS vectors using the QIAprep spin kit (Qiagen).  Purified DNA was digested with 
BamHI and SacII (NEB) to generate compatible fragments of approximately 5.4kb (fUSE5) 
and 4.1kb (fMCS).  The restriction products were precipitated, resuspended, and adjoined 
with the Rapid Ligation kit (Roche). This created a fUSE5-fMCS hybrid intermediate 
containing a targeting peptide insert (CRTIGPSVC or derivatives) and a multicloning site 
(MCS) for insertion of transgene cassettes.    
 To create the targeted AAVP carrying HSVtk, we first subcloned HSVtk into the pAAV-
eGFP plasmid (enhanced GFP; Stratagene) to replace eGFP using the BamHI and NotI 
restriction sites.  The resultant pAAV-HSVtk plasmid was subsequently digested with PvuII 
to produce a ~2.8 kb fragment containing HSVtk with functional inverted terminal repeats 
(ITRs).  The HSVtk fragment was then ligated to a PvuII digested, linearized, and 
dephosphorylated fUSE5-MCS plasmid with the Rapid Ligation kit (Roche). Correct 
orientation of the insert in each construct was verified by restriction and PCR analysis.  
AAVP vectors were isolated, purified, and titered similar to phage clones, described above. 
 
Peptide sequence analysis. To identify motifs matching Tf among phage-displayed 
peptides homing to normal brain, an in-house Peptide Match software was codified in Perl 
5.8.1 based on RELIC (91). The code is based on the standard Basic Local Alignment 
Search Tool (BLAST), and it scores the similarity between the selected peptides and protein 
from the N- to the C-termini by scanning overlapping motifs comprising each seven-mer 
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peptide in one-residue shifts and in both orientations (92).  The peptide-protein similarity 
scores were calculated based on a BLOSUM62 amino acid substitution matrix, modified to 
adjust for rare amino acid representation. In order to discriminate significant similarity from 
non-specific background match, different similarity score thresholds were empirically set for 
selected peptides, based on their population sizes.  Peptide matches are subsequently 
classified according to the BLOSUM62-defined numbers of peptide residues deemed 
“identical,” “highly similar,” or “similar” to the corresponding residue positions within the 
protein. Graphic mapping of peptide sequences along the protein was performed using a 
web-based software codified in Perl 5.8.1 and CGI.  Maps of peptide/protein match hotspots 
were generated with R Project Version 2.2.1. 
 
DNA and RNA isolation from tissue and quantitative real-time PCR.  Total DNA was 
isolated from either 25 mg of tissue, 10 µl of non-coagulated blood, or 1 mm coronal brain 
tissue sections using the DNeasy Blood and Tissue Kit (Qiagen). DNA samples were 
quantified by absorbance measurements (A260) and aliquots were stored at -80°C. The 
amount of phage present in each tissue sample was determined by quantitative PCR using 
the 7500 Fast Real-Time PCR System instrument (Applied Biosystems).  In a final volume 
of 15 µl, each reaction contained 60 ng or 25 ng total DNA, 1x Power SYBR Green PCR 
Master Mix (Applied Biosystems), and oligonucleotide primers amplifying a portion of the 
TetR gene (3.75 picomoles) (93): 
 
fUSE5F1: 5’-TGAGGTGGTATCGGCAATGA-3’  
fUSE5R1: 5’-GGATGCTGTATTTAGGCCGTTT-3’ 
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The following cycle program was used: 
Step 1: 50oC, 2 min 
Step 2: 95oC, 10 min 
Step 3: 95oC, 15 sec 
Step 4: 60oC, 1 min; Repeat steps 3-4 x40. 
 
To validate amplification of the desired product, a dissociation curve analysis with an initial 
denaturation for 15 sec at 95oC followed by sequential temperature elevation from 60oC to 
95oC to re-anneal the products was performed.  For each experiment, standard curves were 
created through serial dilutions of precisely quantitated fUSE5 plasmid, ranging from 2.4 x 
102 to 2.4 x 106 copies, and calculated by the system software (7500 Fast System SDS 
software, version 1.3.1.21, Applied Biosystems) through regression analysis of the PCR 
curve crossing points from the plasmid dilutions.  The phage content within each DNA 
sample was extrapolated through comparison of the observed amplification threshold to the 
calculated standard curve. All amplifications and calculations were performed with an 
ABI7500 Fast system, and all data points, including the standard curve, were determined 
from triplicate reactions. 
 For gene expression studies, two sets of total RNA were independently isolated from 
brain microvessel and parenchyma fractions with the RNeasy Mini Kit (Qiagen). DNA 
synthesis was performed with SuperScript® III First-Strand Synthesis System (Invitrogen) 
according to the manufacturer’s instructions. The following primer pairs were used: 
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slc2a1 (glut-1):  
5’ TTCTCTGTCGGCCTCTTTGT 3’  
5’AGGCCAACAGGTTCATCATC 3’ 
 
VE-cadherin:  
5’ TCATCAAACCCACGAAGTCC 3’  
5’TGTTTTTGCCTGAAGTGCTG 3’ 
 
Occludin:  
5’ CCTACTCCTCCAATGGCAAA 3’  
5’ GGCACCAGAGGTGTTGACTT 3’ 
 
Isolation of brain blood vessels.  Fractionation of brain blood vessels was performed as 
described (94, 95).  Mice aged 3–5 weeks were deeply anesthetized and perfused through 
the heart with 10 mL of PBS. Craniotomy was performed and the meninges were removed 
with cotton swaps.  Brains were removed and homogenized in a 1 mL Dounce tissue grinder 
in ice-cold DMEM-PI containing 0.2% BSA. The resulting homogenate was diluted to a 
final volume of 5 mL, transferred to the top of a 30% (wt/vol) dextran solution, and 
centrifuged for 25 min at 3,000 g at 4°C. The myelin layer and pellet containing blood 
vessels were carefully collected and washed twice in DMEM containing 0.2% BSA. The 
final fractions were resuspended in an adequate volume and used for DNA or RNA 
extraction (see above). 
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Colony counting assay.  Determination of phage content in tissues following systemic 
circulation by bacterial infection has been previously described (87, 90).  Organ samples 
(brain, muscle, pancreas, liver, lung, kidney, and spleen) were weighed and processed in 
triplicate.  Tissues were placed in a Dounce glass tissue grinder containing DMEM-PI and 
1% BSA (DMEM-PI/BSA), homogenized and transferred to a 2 ml eppendorf tube.  Tissue 
samples were then washed three times with ice cold DMEM-PI/BSA, mixed with DMEM-
PI, and vortexed for 30 sec after each wash.  Samples were centrifuged at 4000 rpm for 3 
min, and the supernatant discarded carefully.  After the third wash, samples were briefly 
vortexed to re-suspend and warmed to 37°C before adding host E. coli bacteria (K91kanR).  
We then incubated the admixture with 1.5 ml of host E. coli bacteria (O.D.600 = 2.0) for one 
hour at RT.  The mixtures were transferred to tubes containing 10 ml of LB containing 
tetracycline (20 µg/ml) and kanamycin (100 µg/ml) and incubated at RT for 20 minutes.  
Multiple aliquots were plated in triplicate on LB agar plates containing tetracycline (20 
µg/ml) and kanamycin (100 µg/ml) and incubated at 37°C O/N.  The following day, phage 
content (TU) per mg of tissue was determined by counting formed colonies. 
 
In vitro phage binding assays.  TfR, apo-Tf, holo-Tf, and BSA were coated in triplicate 
wells of a 96-well microtiter plate O/N at 4°C.  Wells were washed twice with PBS, blocked 
with PBS containing 3% BSA for 1 h at RT, and incubated with 109 TU of phage for 1-2 hr. 
Wells were washed extensively with PBS (~12 times), and bound phage were recovered by 
infection with 200 µL of host E. coli bacteria (K91kanR; O.D.600 = 2.0).  The mixtures were 
transferred to LB containing tetracycline (20 µg/ml) and kanamycin (100 µg/ml) at RT for 
20 min then plated in multiple aliquots on LB agar plates containing tetracycline (20 µg/ml) 
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and kanamycin (100 µg/ml).   Plates were incubated at 37°C O/N and resultant colonies 
counted.  To test phage binding inhibition by free iron, an initial solution of 10 mM iron (III) 
phosphate (Fe3PO4) (Sigma) in double-distilled water was used.  Final concentrations of iron 
ranged from 0.01 mM to 0.5 mM, where indicated.  
 
Phage binding assays on cells.  Cell-phage binding assays were performed as described 
(61).  In brief, cultured cells were washed with PBS, detached with 5 mM EDTA, and 
resuspended in DMEM containing 10% FBS.  Cells were manually counted using a 
hemocytometer and resuspended in the appropriate volume.  A total of 106 cells were 
incubated with 109 TU of phage for 2 h on ice in the presence of either apo- or holo-Tf (200 
µg/mL) in 200 µL DMEM.  The liquid cell suspension was added to a 400 µl Eppendorf 
tube containing an organic solution (dibutyl phthalate:cyclohexane, vol/vol, 9:1; ρ = 1.03 
g/ml) and centrifuged at 10,000 g for 10 min.  The tube was immediately snap frozen to 
isolate the pellet.  The tube bottom was carefully cut into an Eppendorf tube and residual 
organic solvent liquid was removed.  The phage-cell pellet was resuspended and incubated 
with 200 µl of host E. coli bacteria (K91kanR; O.D.600 = 2.0).  Phage/bacteria admixture was 
plated in multiple aliquots on LB agar plates containing tetracycline (40 µg/ml) and 
kanamycin (100 µg/ml), incubated at 37°C O/N, and counted for TU determination (see 
above). 
 
Removal of iron from holo-Tf by chelators.  Ten mg of holo-Tf were dissolved in 1 mL 
PBS (O.D.450 = 0.3), and 100 µL of this solution was transferred to Slide-A-Lyzer MINI 
Dialysis Units (Pierce).  Samples were dialyzed in EDTA or DFO solutions.  The final 
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concentrations of chelating agents ranged from 0.05 mM to 50 mM, with minimal alteration 
in the final volume after 24 h.  Transfer reactions were measured spectrophotometrically 
with an O.D.450.  
 
Steady-state fluorescence spectroscopy.  Steady-state tryptophan fluorescence spectra for 
apo-Tf were obtained on a Spectrofluorimeter LS 50B (Perkin-Elmer).  Increasing molar 
ratios of Fe+3, the targeted peptide CRTIGPSVC, or control peptides (control peptide 1: 
CGLPYSSVC; control peptide 2: CSGIGSGGC; control peptide 3: CRFESSGGC and 
control peptide 4: CPQRGVTPC) were incubated O/N at RT with 2 µM apo-Tf in buffer 
containing 100 mM HEPES, 10 mM NH4CO3, pH 7.4.  Samples were excited at 295 nm and 
emission scans were collected from 305 to 400 nm with an excitation slit of 2.5 nm and an 
emission slit of 6 nm. All spectra were corrected for background fluorescence by subtraction 
of the appropriate blanks. 
 
Circular dichroism (CD).  CD spectra for apo-Tf were recorded on a Jasco J720 
spectropolarimeter (JASCO Europe) from 230 to 320 nm, with a bandwidth of 1 nm and 
integrated for 1 sec at 0.2 nm intervals.  Samples were measured at RT using cuvettes with a 
2-mm path length. Absorbance values of Fe+3 and peptide alone were subtracted from the 
results.  Increasing concentrations of Fe+3, the targeted peptide CRTIGPSVC, or control 
peptides (control peptide 1: CGLPYSSVC; control peptide 2: CSGIGSGGC; control peptide 
3: CRFESSGGC and control peptide 4: CPQRGVTPC) were titrated in 100 µM of apo-Tf in 
buffer containing 100 mM HEPES, 10 mM NH4CO3, pH 7.4.  The data were expressed as 
mean residue ellipticity, [θ], in deg cm2 / dmol, which was calculated from [θ] = (d x s x 
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M)/(c x l), where d denotes observed ellipticity (the displacement in cm from the baseline), s 
sensitivity in mdeg/cm, M, the mean residue weight, c, protein concentration in mg/mL and 
l, cell path length.  The concentrations of protein were kept at 8 mg/mL. 
 
High-density tissue microarrays (TMA).  The construction of the human glioma TMA 
was previously described (96).  Briefly, tissue arrays were constructed with a manual tissue 
arrayer (Beecher Instruments) with tissue cores extracted from formalin-fixed, paraffin-
embedded archival tissue blocks obtained from the brain tumor bank at UTMDACC. The 
TMA included primary human gliomas with all histologic subtypes and grades of diffuse 
gliomas as codified by the World Health Organization classification (4, 5), including 
glioblastoma multiforme (GBM), anaplastic astrocytoma (AA), anaplastic 
oligodendroglioma (AO), oligodendroglioma (O), anaplastic mixed oligoastrocytoma 
(AMOA), mixed oligoastrocytoma (MOA), gliosarcoma (GS), and low-grade diffuse 
astrocytoma (LGA).  LGAs were not analyzed here because of their small sample size (n=4). 
 
Immunohistochemistry.  Immunohistochemistry on sections of formalin-fixed, paraffin–
embedded mouse and human tissue was performed with a labeled streptavidin biotin 
(LSAB) + peroxidase kit (DAKO).  Slides were deparaffinized and rehydrated with xylene 
and graded concentrations of alcohols, blocked for endogenous peroxidases, and treated in a 
microwave oven with an antigen retrieval solution (DAKO).  Slides were blocked for non-
specific protein binding and treated with one of the following primary antibodies: (i) 
polyclonal rabbit anti-bacteriophage antibody (1:500 dilution), (ii) polyclonal rabbit anti-
CD31 antibody (1:50 dilution), or (iii) polyclonal goat anti-TfR (1:50 dilution).  After 1 h, 
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slides were washed three times with 20 mM Tris-buffered saline (TBS) containing 0.1% 
Triton X-100.  Slides were next incubated for 1 h at RT with a peroxidase-conjugated anti-
rabbit secondary antibody.  Slides were washed three times with TBS containing 0.1% 
Triton X-100 and were developed with the specific substrate 3,3’-diaminobenzidine (DAB).  
Immunohistochemistry on glioma tissue microarrays and glioma xenografts were performed 
on an automated immunohistochemical autostainer (Lab Vision Corp.).  Stained TMAs were 
evaluated and scored by a pathologist.  Detection of apoptosis in paraffin-embedded 
specimens was performed with the FragEL™ DNA Fragmentation Detection Kit 
(Calbiochem) according to the manufacturers instructions.  Hematoxylin was used as a 
nuclear counterstain in all experiments.  
 
Immunofluorescence.  Fluorescence immunohistochemistry was performed on cryostat 
sections (60 – 80 µm thickness) from 1% PFA-fixed tissues.  Slides were washed three times 
with PBS and once with PBS containing 0.3% Triton X-100 (PBST; 5 min per wash) 
followed by non-specific protein block for 1 h with 5% normal serum diluted in PBST. 
Tissue sections were incubated with one or more of the following primary antibodies diluted 
in PBST containing 1% appropriate normal serum at RT for 1 h: (i) monoclonal rat anti-
CD31 (1:500 dilution), (ii) polyclonal rabbit anti-bacteriophage (1:5000 dilution), (iii) 
polyclonal goat anti-TfR (1:1000 dilution).  Sections were rinsed three times and stained for 
1 h with appropriate Cy3-conjugated and FITC-conjugated secondary antibodies.  Slides 
were washed three times in PBST, fixed in 4% PFA for 2 min, and washed three times with 
PBS.  Fluorescence images were captured on an IX70 inverted fluorescence microscope 
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(Olympus).  Confocal images were acquired on a laser scanning confocal microscope 
(Zeiss). Image analysis was performed with the Zeiss LSM 3.2 software package.  
 
Radiolabeled substrate synthesis and quantification.  Radiolabeled [18F]-FEAU was 
synthesized to radiochemical purity (> 99%) using 5-ethyluracil-2,5-bis-trimethylsilyl ether 
as the pyrimidine base for condensation with 1-bromo-2-deoxy-2-[18F]fluoro-3,5-di-O-
benzoyl-α-D-arabinofuranose (97, 98).  For quantification of [18F]-FEAU radioactivity, 
regions of interest were digitally drawn on images and the measured values converted from 
nCi/mm3 into percentage of injected dose per gram of tissue [%ID/g] (79, 80). 
 
Targeted molecular-genetic imaging.  Orthotopic brain tumor-bearing animals received a 
single dose (1011 TU iv per mouse) of CRTIGPSVC-AAVP-HSVtk or control ~7 d after 
tumor implantation.  A combination of positron emission tomography (PET) and computed 
tomography (CT) scans following iv administration of the radiolabeled nucleoside analog 
[18F]-FEAU were used to determine HSVtk expression.  For individual PET images, a 
microPET R4 (Concorde Microsystems) equipped with a computer-controlled positioning 
bed in a 10.8-cm transaxial and 8-cm axial field of view with no septa and operating in 3D 
list mode was used.  Combined PET/CT imaging was performed with an Inveon micro-
PET/CT scanner (Siemens Preclinical Solution).  Glioma-bearing mice were anesthetized 
(2% isoflurane in 98% oxygen), temperature maintained at 38°C with a heat lamp, and 
submitted for imaging 2 h following intravenous [18F]-FEAU administration.  The microCT 
imaging parameters were: x-ray voltage of 80kVp, anode current of 500 µA, and exposure 
time of 300-350 milliseconds for each of the 360 rotational steps.  Images were 
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reconstructed by a two-dimensional ordered subsets expectation maximization (OSEM) 
algorithm.  PET and CT image fusion and image analysis were performed with vendor 
software ASIPro version 5.2.4.0 (Siemens Preclinical Solution).  
 
Targeted therapy. Glioma-bearing animals (n=10 animals/group) received a single dose 
(1011 TU iv per mouse) of CRTIGPSVC AAVP-HSVtk or control ~7 d after intracranial 
tumor implantation.  Treatment with ganciclovir (GCV; 80 mg/kg/day, ip) was initiated 7 d 
after AAVP administration and continued for 5 d.  Animals were monitored and euthanized 
at the first sign of intracranial tumor burden.  Following the treatment protocol, animals 
were euthanized and tumor sizes measured.  Tissues were placed in 10% neutral buffered 
formalin for histological and immunohistological analyses. 
 
Statistics. Experimental data values are expressed as means±standard error of the mean 
(SEM) from at least triplicate experimental data sets.  In most settings, test and control data 
were compared using a Student’s t test or ANOVA, where appropriate, and p values less 
than 0.05 were considered significant. 
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CHAPTER 3: RESULTS 
Chapter 3.1: Receptor-mediated delivery of targeted phage particles across the intact 
BBB.   
To gain insight into the repertoire of cell surface receptors present on the brain 
endothelium and identify ligand-receptor systems for targeted delivery, we employed an in 
vivo phage display screening strategy using a library of random CX7C peptides (C, cysteine; 
X, any residues) (62, 67, 68, 88, 99).  The phage library was intravenously administered into 
normal mice (66) and allowed to circulate for endothelial cell internalization and transport 
across the intact BBB in vivo.  Following 3 rounds of serial selection (panning), we 
recovered an enriched population of brain-homing phage.  The brain-targeting phage pool 
was analyzed by a series of custom bioinformatics software packages (62, 68) to identify 
candidate motifs and to minimize or eliminate background for further evaluation (62, 68).  
We then applied a basic local alignment and search tool (BLAST) of selected sequences 
online to detail protein alignment and to identify peptides with high similarity.  More than 
30 non-redundant peptide sequences (~20% of the total) showed similarity to the iron-
binding molecule transferrin (Tf).  This sub-pool was used for further analysis and 
prioritization. Three main clusters of candidate Tf-like motifs were identified and enclosed 
within the N-lobe of Tf: Clusters #1 and #3 matched to two distinct segments of domain N1 
(at the N- and C-termini), while Cluster #2 was centered within domain N2 (Fig. 4).  Three-
dimensional models of the iron-bound Tf N-lobe (Fig. 5A, residues 1 – 331) and iron-bound 
Tf complexed to TfR (Fig. 5B) positioned cluster 2 around the iron atom, within the Tf iron-
binding cleft. Clusters #1 and #3 were located on the exposed surface of Tf (100).  Given the 
sequence similarity to an exposed surface of Tf, we initially focused our functional analysis 
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Figure 4. Sequence alignment of phage clones recovered from in vivo phage display 
screening.  The scheme depicts the overall structure of the N-lobe half-molecule of 
transferrin.  Domains N1 and N2 are indicated.  The numbers represent the six consensus 
disulfide bonds: Cys10-Cys49, Cys20-Cys40, Cys119-Cys195, Cys159-Cys175, 
Cys162-Cys180, and Cys172-Cys178, respectively. 
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Figure 5.  Peptide cluster mapping of transferrin.  (A) Ribbon diagram showing the 
structural organization of iron-loaded transferrin and location of the peptide clusters. (B) 
Side-view of the transferrin:transferrin receptor molecular complex.  N- and C-lobes are 
shown. 
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on the cyclic targeting peptide CRTIGPSVC, originally grouped in cluster 1.  The remaining 
candidate peptides were not functionally pursued here.   
To evaluate and confirm the targeting attributes of the selected peptide in vivo, we 
administered the CRTIGPSVC-phage intravenously into normal mice and first assessed 
homing by recovery from tissue homogenates, followed by counting of transducing units 
(TU) (not shown) and quantitative real-time PCR (Fig. 6).  Non-targeted (insertless) phage 
and homing to non-CNS organs (shown is muscle) served as negative controls (Figs. 6 and 
7).  Phage was intravenously (iv) administered into tail veins of mice, and brains and control 
organs were surgically collected 10 min, 30 min, and 24 h later.  Phage DNA was amplified 
by quantitative real-time PCR, and we detected ~100-fold more CRTIGPSVC-phage 
particles in the normal brain following a 10 min circulation compared to insertless phage 
(Fig. 6).  A similar result was obtained at 30 min (Fig. 6), with a reduction to ~40-fold 
difference detected at 24 h post-administration (Fig. 6).  Homing to skeletal muscle was at 
background levels for all timepoints.  Next, to evaluate phage clearance and assess the 
contribution of phage degradation in targeting differences, we performed pre-clinical 
pharmacokinetic studies.  We observed no significant differences in the half-lives of targeted 
and insertless phage in the blood of normal mice (Fig. 8) suggesting that superior uptake of 
targeted phage in the brain is mediated by specific ligand-receptor interactions and not an 
event of differential circulation.  Lastly, brain microvessel separation from the brain 
parenchyma was used to confirm the ability of the CRTIGPSVC-phage to cross the intact 
BBB (Fig.  9A) (94, 95, 101). Normal mice were intravenously injected with targeted or 
insertless phage and brains were collected after 10 min, 30 min, and 24 h of systemic 
circulation.  The tissue was homogenized and fractionated on a gradient of 30% dextran
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Figure 6. Targeting specificity of phage displaying the peptide CRTIGPSVC in 
normal mouse brain.  The homing specificity of CRTIGPSVC-phage and insertless-
phage in normal brain compared to non-brain control organ (shown is muscle).  
CRTIGPSVC-phage and insertless phage were administered intravenously into mice.  
Phage was allowed to circulate for 10 min, 30 min and 24 h, and tissues were recovered 
and processed as described. 
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Figure 7.  Homing of CRTIGPSVC-phage and insertless phage to non-CNS control 
organs.  Mice were injected with 1010 TU of phage and organs were collected after 10 
min (A), 30 min (B), and 24 h (C) of systemic circulation.  Accumulation of phage 
particles is observed in the spleen and liver under all experimental conditions, a 
phenomenon caused by the non-specific clearance of phage within the reticulo-
endothelial system (RES). 
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Figure 8. Pharmacokinetic study of targeted and insertless phage.  CRTIGPSVC-
phage and insertless phage were administered into normal mice and the half-life in blood 
was established.  Data depict similar clearance irrespective of the presence of an insert 
peptide. 
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Figure 9. Brain microvessel depletion confirms blood-brain barrier transport.  (A) 
Fractionation of brain microvessels and parenchyma confirmed the ability of the 
CRTIGPSVC-phage to cross the intact blood brain barrier. (B) Separation of 
microvessels from the brain parenchyma was confirmed by real-time quantitative PCR.  
Shown are markers of brain capillaries (slc2a1 and Occludin) and large blood vessels 
(VE-cadherin). 
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solution (wt/vol).  Quantitative real-time PCR demonstrated the presence of CRTIGPSVC-
phage in both fractions (blood vessels and blood vessel-depleted brain parenchyma).  
Insertless phage was not detected in the parenchyma fraction (Fig. 9A).  We further used 
real-time PCR to confirm partial purity of the isolated fractions using genes specific for 
capillaries and endothelial cells (Fig. 9B).  
 
Chapter 3.2: The targeting peptide CRTIGPSVC binds to Tf/TfR through an allosteric 
mechanism.  
Having shown that targeted phage particles displaying the CRTIGPSVC peptide 
crossed the intact BBB, we next attempted to elucidate the molecular mechanism(s) 
mediating its transport from blood into normal brain.  First, to establish whether 
CRTIGPSVC is a mimic of Tf, we evaluated the binding of CRTIGPSVC-phage to cells 
stably over-expressing human TfR and parental cells using a phage-based cell separation 
assay (Fig. 10) (61).  To determine binding specificity, we tested the affects of apo-Tf (iron-
free, open conformation) and holo-Tf (iron-containing, closed conformation) on the binding 
of phage to the cell surface.  Unexpectedly, we observed enhanced binding when apo-Tf was 
added to the system (Student’s t test, p<0.05).  This result indicated that CRTIGPSVC-
phage interacts with apo-Tf resulting in enhanced binding to TfR.  To more accurately 
determine CRTIGPSVC binding characteristics, we next analyzed the binding of 
CRTIGPSVC-phage to TfR, apo-Tf, and holo-Tf in a cell-free system.  Insertless phage and 
BSA were used as negative controls. Consistently, we observed enhanced binding of 
CRTIGPSVC-phage to apo-Tf compared to TfR or holo-Tf (Fig. 11).   As commercially 
available apo-Tf preparations often contain minute amounts of iron-loaded Tf contaminants
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Figure 10.  CRTIGPSVC-phage interacts with apo-transferrin.  Binding of phage to 
rat gliosarcoma 9L cells and 9L cell expressing human transferrin receptor (9L3.9) in the 
presence of apo-transferrin and holo-transferrin.  Statistically significant (*Student’s t 
test, p<0.05) binding to 9L3.9 in the presence of apo-Tf was observed with 
CRTIGPSVC-phage compared to holo-Tf. 
 46 
          
    
Figure 11.  CRTIGPSVC-phage binds to apo-transferrin.  Binding assays revealed 
that CRTIGPSVC-phage target apo-Tf in vitro.  Insertless phage and BSA served as 
negative controls. 
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that could bias interpretation of our data, we used increasing concentrations of EDTA (from 
0.05 mM to 50 mM) to remove iron from commercial holo-Tf and to generate an “iron-free 
apo-Tf preparation” (Fig. 12A).  Desferroxamine (DFO), an effective free-iron-chelating 
agent that does not remove iron from holo-Tf, served as a negative control (102).  We 
validated transfer of iron from holo-Tf to the chelating agents through spectrophotometric 
monitoring of changes in light absorption (Fig. 12A).  Increasing amounts of EDTA linearly 
reduced light absorption, data indicating release of iron from holo-Tf (Fig. 12A); no changes 
in absorption were detected when holo-Tf was dialyzed against DFO under the same 
experimental conditions.  Total removal of iron and change in protein conformation were 
achieved with 50 mM EDTA.  
We next tested the binding of CRTIGPSVC-phage to the “iron-free apo-Tf”, in the 
presence of increasing concentrations of EDTA or DFO.  As controls, we used apo- and 
holo-Tf.  Phage displaying the peptide CRTIGPSVC bound only to the commercial apo-Tf 
preparation and to that obtained after dialysis of holo-Tf with 50 mM EDTA (Fig. 12B, 
arrows).  As further confirmation of our previous results, we did not detect binding of 
CRTIGPSVC-phage to holo-Tf.  
Given that CRTIGPSVC-phage binds selectively to apo-Tf, we hypothesized that the 
CRTIGPSVC peptide might functionally mimic iron.  If so, it would stand to reason that 
binding of CRTIGPSVC, like binding of iron, would induce allosteric conformational 
changes in apo-Tf.  This would allow for Tf binding to TfR, receptor dimerization, receptor 
endocytosis, and ultimately release of the peptide-targeted phage into the cytoplasm of TfR-
positive cells.  To test this hypothesis, we evaluated whether free iron and/or CRTIGPSVC 
synthetic peptide would compete with the binding of CRTIGPSVC-phage to apo-Tf.  We
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Figure 12. Removal of iron from holo-transferrin by EDTA.  (A) The transfer 
reaction and removal of iron was measured spectrophotometrically at 450 nm.  DFO was 
used as a control.  (B) Phage binding assays to commercial apo-Tf and apo-Tf obtained 
after dialysis of holo-Tf with EDTA.  The CRTIGPSVC-phage binds only to apo-Tf 
(arrows).  No phage binding to holo-Tf was detected above background.  Experiments 
were performed three times and a representative experiment is shown.  
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designed a series of phage binding assays in vitro to apo- and holo-Tf in the presence of 
several concentrations of ferric iron (Fe+3), chelating agents, and CRTIGPSVC peptide 
(Figs. 13 and 14).  We observed that iron at concentrations ranging from 0.01-0.5 mM 
abrogated binding of CRTIGPSVC-phage to apo-Tf (Fig. 13A) whereas no major alterations 
were observed in the binding of targeted phage to holo-Tf (Fig. 13B).  Consistently, the 
effect of iron on the binding of peptide-targeted phage particles to apo-Tf or holo-Tf was 
reversed by the addition of EDTA (Fig. 14).  In vitro phage binding assays revealed 
concentration-dependent iron chelation with EDTA, which reversed iron-induced binding 
inhibition of CRTIGPSVC-phage to apo-Tf (Fig. 14A).  We noted no changed in 
CRTIGPSVC-phage binding to holo-Tf in the same experimental setting (Fig. 14B).  The 
same results were obtained with the CRTIGPSVC synthetic peptide, where increasing 
peptide concentrations abrogated binding of targeted phage to apo-Tf (data not shown).  
Together, these data suggest that CRTIGPSVC and iron have similar allosteric effects on 
apo-Tf, CRTIGPSVC binds to apo-Tf, and that CRTIGPSVC-phage functionally mimics 
iron.  Moreover, these data are consistent with the hypothesis that selective internalization of 
the Tf:TfR:CRTIGPSVC complex into TfR-positive cells is mediated by conformational 
changes induced by CRTIGPSVC binding to apo-Tf.   
To evaluate this working hypothesis, we applied optical methodologies, initially 
using analysis by steady-state fluorescence (Fig. 15) (103-106).  First, we assigned changes 
in fluorescence spectra to apo-Tf in the absence or presence of Fe3+ (Fig. 15A).  Next, we 
used increasing concentrations of the CRTIGPSVC peptide to evaluate changes in apo-Tf 
conformation as indicated by changes in fluorescence spectra; we observed a gradual shift of 
the apo-Tf fluorescence spectra in the presence of increasing amounts of the CRTIGPSVC
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Figure 13. In vitro phage binding assay to apo- and holo-transferrin in the presence 
of free iron. (A) Iron inhibits the binding of CRTIGPSVC-phage to apo-transferrin in a 
concentration-dependent manner, but not its binding to holo-transferrin (B). 
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Figure 14.  EDTA-mediated chelation abolishes phage binding to apo-transferrin.  
The effect of iron on the binding of phage to apo-transferrin was reversed by EDTA, but 
no effect was observed with holo-transferrin.  In vitro binding assays were performed in 
96-well plates coated with either apo-transferrin (A) or holo-transferrin (B), in the 
presence of iron and increasing amounts of EDTA. 
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Figure 15. CRTIGSPVC peptide-induced conformational change assessed by 
steady-state fluorescence analysis.  Steady-state emission spectra of apo-Tf in the 
presence of iron (A) or distinct concentrations of the CRTIGPSVC peptide (B).  Four 
different peptide sequences (C) were used as control.  Control peptide 1: CGLPYSSVC; 
Control peptide 2: CSGIGSGGC; Control peptide 3:CRFESSGGC; and Control peptide 
4:CPQRGVTPC.   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peptide (Fig. 15B); under these experimental conditions, the interaction reached saturation at 
1:6 molar ratio (apo-Tf:CRTIGPSVC).  Finally, a panel of unrelated control peptides served 
to demonstrate that the phenomenon is specific to the interaction between apo-Tf and 
CRTIGPSVC (Fig. 15C).  Consistent experimental results were obtained with another 
optical method, circular dichroism (CD) analysis (Fig. 16).  As expected, adding Fe+3 to 
apo-Tf generated a shift in the spectra reflecting the known iron-induced conformation 
change from apo-Tf to holo-Tf (Fig. 16A) (107-109).  The CRTIGPSVC peptide also 
mediated conformation changes in apo-Tf (Fig. 16B), with no such changes detected with 
addition of unrelated control peptides (Fig. 16C).  Together, these data (Figs. 15 and 16) 
strongly suggest that the CRTIGPSVC peptide mediates a protein conformational change in 
apo-Tf.  One should note that, unlike iron, the peptide does not appear to mediate a full 
conformational change from apo-Tf to holo-Tf.  Thus, further studies will be required to 
understand the precise nature of this peptide-protein interaction.   
 
Chapter 3.3: CRTIGPSVC-phage targets Tf:TfR in vivo.   
Because CRTIGPSVC-phage binds to apo-Tf in vitro, and the CRTIGPSVC peptide 
changes the conformation of apo-Tf in a concentration-dependent manner, we next asked 
whether the same mechanism would be implicated in the homing and transport of phage 
particles across the BBB in vivo.  Moreover, as the over-expression of TfR has been 
suggested in primary brain tumors (46, 110), and as TfR has the highest gene expression 
ratio in glioblastoma compared to normal brain (9) (Table 1), we chose to study the 
targeting properties of CRTIGPSVC-phage in an orthotopic model of human-derived 
glioblastoma multiforme (46, 47, 86, 110). 
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Figure 16. CRTIGSPVC peptide-induced conformational change assessed by 
circular dichrosim analysis.  Near UV-CD spectra of apo-transferrin in the presence of 
iron (A) or distinct concentrations of the CRTIGPSVC peptide (B). Four different 
peptide sequences (C) were used as controls.  Control peptide 1: CGLPYSSVC; Control 
peptide 2:CSGIGSGGC; Control peptide 3: CRFESSGGC; and Control peptide 4: 
CPQRGVTPC.  Insets show CD spectral region between 230 and 250 nm. 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First, to establish whether the U87-MG-derived xenograft would serves as a suitable 
model, we compared the expression of TfR in normal brains and in human glioma 
xenografts by fluorescence immunohistochemistry (Fig. 17).  CD31 (PECAM-1) was used 
as a standard vascular marker (Fig. 17A and D).  While the expression of TfR was moderate 
and restricted to blood vessels in the normal brain (Figure 17A to C), we observed robust 
expression of TfR in both tumor blood vessels (arrows) and tumor stroma (arrowheads) 
(Figure 17D to F). These data established that the human-derived malignant glioma 
xenografts were an appropriate experimental system for the study of Tf:TfR:peptide-
mediated phage targeting and delivery in vivo. Next, the binding capacity and targeting 
properties of the CRTIGPSVC-phage were compared in normal tissue and tumor. Tumor-
bearing animals were iv administered with phage, and tumor and contralateral brain 
hemisphere (normal tissue) were collected after 10 min, 30 min, and 1 h of systemic 
circulation (Fig. 18).  We obtained coronal brain sections (each ~1 mm thick), isolated total 
DNA and amplified phage DNA for localization.  We also obtained muscle, pancreas, liver, 
lung, spleen, and kidney as control organs (Fig. 19).  Representative photomicrographs of 
hematoxylin and eosin (H&E)-stained brain slices illustrate brain structures present in 
coronal sections from which total DNA was recovered (Fig. 18A). Quantitative real-time 
PCR was then used to measure the levels of phage particles present in normal brain tissue 
compared to tumor samples and control organs. After 10 min of circulation, high levels of 
the CRTIGPSVC-phage were observed in each normal brain slice whereas control insertless 
phage was not detected. In contrast, comparable levels of both targeted and insertless phage 
were obtained in tumor (Fig. 18B, boxed).  However, after 30 min, the same amount of 
targeted phage was detected in the tumor while the number of phage particles in normal
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Figure 17. Expression of transferrin receptor in normal brain and human 
glioblastoma xenograft.  (A to F) CD31 (green) and transferrin receptor (red) 
immunofluorescence demonstrate expression of TfR in both normal (A to C) and tumor 
tissues (D to F).  (E) High levels of expression of TfR, in parallel with the increased 
capillary density are observed in brain tumor.  (F) Merged image shows co-localization 
of TfR and CD31 in angiogenic blood vessels of human glioblastoma xenografts.  
Arrow: tumor blood vessels; arrowhead: tumor parenchymal cells. 
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Figure 18. CRTIGPSVC-phage targets orthotopic brain tumors.  (A) Schematic 
representation of brain slicing technique and quantitative real-time PCR used to 
demonstrate that CRTIGPSVC-phage crosses the BBB. Step 1: Phage was injected 
intravenously into tail veins of mice. Step 2: Brain and control organs were collected. 
Coronal brain slices 1 mm thick were obtained with the aid of a brain-slicer mold.  
H&E-stained sections illustrate prominent tissue components: the lateral ventricle (LV, 
slice 2), hippocampus (Hip, slices 4 and 6), and cerebellum (slice 9). Step 3: Total DNA 
of each brain slice was purified and used as template for phage DNA amplification and 
quantification by quantitative real-time PCR. (B to D) Quantification of phage homing to 
tumor and normal brain after 10 min (B), 30 min (C) and 1 h (D) of systemic circulation. 
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Figure 19. Homing of CRTIGPSVC-phage and insertless phage to non-CNS control 
organs.  Mice were injected with 1010 TU of phage and organs were collected after 10 
min (A), 30 min (B), and 24 h (C) of systemic circulation.  RES, reticulo-endothelial 
system. 
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brain slices was markedly reduced. Notably, insertless phage was not observed in either 
tumor or normal brain (Fig. 18C).  At 1 h post targeted phage administration, we detected 
~1.6 x 104 TU/60 ng DNA in the tumor (Fig. 18D, boxed), whereas normal brain tissue and 
insertless phage showed phage DNA only at background levels.  In support of our original 
findings, pharmacokinetic studies of phage half-life in blood illustrated little difference 
between CRTIGPSVC-phage and insertless phage in animals bearing orthotopic brain 
tumors (Fig. 20).  To confirm tumor targeting specificity, we assessed CRTIGPSVC-phage 
localization in mice bearing subcutaneous human xenografts after 10 and 30 min of systemic 
circulation, compared to control phage (Fig. 21A).  Of note, the number of targeted phage 
particles recovered in subcutaneous tumors was ~10-fold lower than that obtained in 
intracranial tumors given the same injection titer; this result suggests that potentially more 
than one targeting mechanism may be involved in the setting of a compromised BBB. 
Moreover, we observed phage accumulation in the spleen and liver of mice at all time points 
(Fig. 19), a result of the long-established pattern of non-specific particle clearance in the 
reticulo-endothelial system (66, 67, 111). Finally, similar to data obtained from the 
orthotopic model, pharmacokinetic studies showed no difference in the circulation half-lives 
of peptide-targeted phage versus control phage in mice bearing subcutaneous tumors (Fig. 
21B).  Clearly, a distinct phage distribution profile is obtained in brains with tumor, a result 
indicative that phage-targeting properties are largely dictated by receptor expression and 
accessibility to the circulating ligand peptide (112).  Additional known factors such as 
increased vascular permeability leading to increased retention within tumors and increased 
activity of tumor endothelium contribute to the enhanced targeting by CRTIGPSVC-directed 
phage particles (112, 113).  Future studies will be required to elucidate the relative 
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Figure 20. Pharmacokinetic study of blood half-life for CRTIGPSVC and insertless 
phage in tumor bearing mice. CRTIGPSVC-phage and insertless phage were 
administered into mice bearing intracranial tumors and the half-life in blood was 
established.  Data depict similar clearance irrespective of the presence of an insert 
peptide.  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Figure 21. CRTIGPSVC-phage targets subcutaneous brain tumor xenografts.  (A) 
Tumor bearing mice were administered with targeted CRTIGPSVC-phage or insertless 
phage.  Control organs and tumors were collected after 10 min, 30 min, and 24 h of 
systemic circulation.  (B) Pharmacokinetic study of the half-life of CRTIGPSVC- or 
insertless phage in blood. 
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contribution of each individual non-mutually exclusive mechanism(s) in the peptide-
mediated brain tumor selectivity.  
To evaluate CRTIGPSVC-phage localization, we next used immunohistochemistry 
to detect phage within tumors.  Immunohistochemistry revealed specific, punctate staining 
of phage within the tumor vasculature (Fig. 22A).  Strong immunostaining of phage 
particles was also detected in the tumor parenchyma, data demonstrating passage of 
CRTIGPSVC-phage from glioma-associated blood vessels to tumor cells (Fig. 22B to E, 
arrowheads).  We observed no phage staining in tumors from animals injected with 
insertless phage (Fig. 22F) as well as little phage detected in unrelated regions of the brain, 
such as cerebral cortex (Fig. 22G) and caudate/putamen (Fig. 22H).  Next, given the 
vascular localization of CRTIGPSVC-phage, we used fluorescence immunohistochemistry 
in thick (60-80 µm) frozen tissue sections to visualize the distribution of phage within the 
CD31 positive vasculature in three-dimensions (Fig. 23). CRTIGPSVC-phage was widely 
and homogenously distributed within the tumor vasculature but not the blood vessels of 
normal tissue at 30 min (Fig. 23A to C).  At the same timepoint, no signal was exhibited by 
insertless phage within either the tumor or normal brain tissue (Fig. 23D to F).  
By confocal microscopy, we confirmed the CRTIGPSVC-phage targets and co-
localizes with cells expressing the transferrin receptor.  Thick sections of frozen brain from 
tumor-bearing animals systemically receiving CRTIGPSVC-phage iv were analyzed for the 
presence of CD31 (Fig. 24A), TfR (Fig. 24B), and phage (Fig. 24C); TfR and phage 
immunoreactive particles were found to coincide with blood vessels (Fig. 24D).  Moreover, 
CRTIGPSVC-phage and TfR colocalized with tumor parenchymal cells (Figure 24E,
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Figure 22. CRTIGPSVC-phage targets human glioblastoma in vivo. 
Immunohistochemistry of CRTIGPSVC-phage after systemic circulation into human-
derived glioblastoma xenograft-bearing mice.  Staining of phage was observed in tumor 
blood vessels (A; arrows) and glioma cells (B to E; arrowheads).  (F) Insertless phage 
was used as a negative control.  Other areas of the brain such as (G) cerebral cortex and 
(H) caudate/putamen showed only background staining.   
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Figure 23. CRTIGPSVC-phage localizes to tumor blood vessels.  
Immunofluorescence of phage (red) and CD31 (green) revealed accumulation of 
CRTIGSPVC-phage particles in tumor blood vessels but not in normal tissue (A to C).  
Insertless phage, used as a negative control, revealed little or no staining (D to F). 
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Figure 24. CRTIGSPVC-phage co-localizes with transferrin receptor in tumors.  
Confocal fluorescence microscopy showed co-localization of (A) CD31, (B) transferrin 
receptor, and (C) phage in blood vessels.  (D) Merge of images (A to C). Arrowheads 
point to protein co-localization.  (E) Phage particles co-localized to transferrin receptor-
expressing cells in the tumor parenchyma (arrows). 
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arrows), consistent with the interpretation that the mechanism by which CRTIGPSVC-
phage binds and translocates into the tumor vasculature is mediated by the Tf:TfR protein 
complex.  
 
Chapter 3.4: Targeted transgene delivery and molecular imaging of brain tumors.   
We showed that CRTIGPSVC-phage preferentially targets TfR-expressing cells and 
demonstrated that transport of phage into normal brain and brain tumor vasculature is likely 
mediated by the Tf:TfR molecular complex.  Next, to begin to examine the translational 
potential of this discovery, we generated a CRTIGPSVC-displaying AAVP vector to merge 
gene delivery and molecular imaging in an orthotopic preclinical model of human glioma 
(77-79, 82, 114).  A CRTIGPSVC-AAVP construct carrying the Herpes simplex virus 
thymidine kinase gene (HSVtk) was engineered; the HSVtk transgene can serve as both a 
suicide gene strategy when combined with drugs such as ganciclovir (GCV) or as a reporter 
for molecular-genetic imaging of tracers such as [18F]-FEAU (77, 79, 80).  We delivered 
CRTIGPSVC-AAVP-HSVtk or control insertless-AAVP-HSVtk to cohorts of brain tumor-
bearing mice (n=10/group).  Animals treated with vehicle were also used as controls (n=10).  
Both CRTIGPSVC-AAVP and insertless-AAVP groups were treated with GCV for 5 days 
(80 mg/kg/day, ip) and response to treatment was assessed by measurement of tumor areas 
(Fig. 25) and by histopathological examination (Fig. 26).  After GCV-based therapy, the 
size of tumors in mice that received CRTIGPSVC-AAVP-HSVtk was significantly smaller 
(Student’s t test, p<0.001) than that in mice receiving insertless-AAVP-HSVtk or vehicle 
alone (Fig. 25).  Immunohistochemical studies for CD31 expression demonstrated that 
systemic administration of CRTIGPSVC-AAVP-HSVtk followed by GCV therapy caused
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Figure 25. Targeted therapy of an orthotopic model of human-derived glioblastoma 
xenograft.  Tumor growth suppression by CRTIGPSVC-AAVP-HSVtk transduction plus 
treatment with ganciclovir (GCV).  Cohorts of immunodeficient nude mice (n=10) with 
established intracranial tumors derived from U87-MG cells received a single systemic 
administration of targeted CRTIGPSVC-AAVP-HSVtk (5 x 1010 TU) or control 
insertless-AAVP-HSVtk.  Mice received GCV from 7 d post systemic iv AAVP 
administration until the end of the experiment (daily GCV dose ip for 5 d).  Untreated 
group received vehicle alone.  Shown are the means of tumor area±standard deviations 
(SD) and a statistically significant reduction in tumor volume was observed with 
CRTIGPSVC-AAVP therapy (***Student’s t test, p<0.001). 
69 
         
    
Figure 26. Histopathologic analysis of brain tumors following targeted therapy.  
CD31 staining was performed on paraffin embedded brain tumor tissue sections of 
animals treated with CRTIGPSVC-AAVP or control insertless-AAVP.  Untreated 
animals received only vehicle.  Arrows point to disrupted blood vessels.  Negative 
control: tumor tissue stained with IgG control isotype. 
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targeted destruction of capillary-like blood vessels, in line with immunohistochemical data 
obtained in our experimental model of glioblastoma multiforme (Fig. 26). This effect was 
not observed in animals treated with insertless-AAVP or vehicle.  Next, we tested the 
efficacy of clinically applicable molecular-genetic PET imaging with [18F]-FEAU combined 
with CT scan imaging for noninvasive monitoring of the cellular dynamics and 
heterogeneity of HSVtk reporter gene expression in living orthotopic glioma-bearing mice 
(Fig. 27).  PET imaging with [18F]-FEAU was performed 7 d and 10 d after vector 
administration to assess the localization and magnitude of HSVtk expression.  No specific 
transgene expression was detected 7 d after AAVP administration iv (data not shown).  In 
contrast, we observed significant (Student’s t test, p<0.05) levels of HSVtk expressed as 
relative tumor/muscle injected dose/gram (ID/g) after 10 d in the tumors of animals 
administered with CRTIGPSVC-AAVP-HSVtk compared to the control group (Fig. 27A).  
Combined micro-PET/CT images in axial, coronal, and sagittal planes in tumor-bearing 
mice revealed heterogeneous targeting of intracranial human glioblastoma xenografts with 
little or no signal in the normal brain tissue (Fig. 27B), whereas control insertless-AAVP 
yielded negative results in both normal brain and tumor (Fig. 27C); these data were 
consistent with our immunohistochemical stainings following phage administration.  Finally, 
terminal deoxynucleotidyl-transferase-mediated dUTP-biotin nick end labeling (TUNEL) 
staining clearly confirmed a heterogeneous distribution of apoptotic endothelial and glioma 
cells within the tumor but little to no apoptosis observed in tumors from mice that received 
either insertless-AAVP-HSVtk or vehicle alone (Fig. 28A to D). Together, these results 
demonstrate that the level of HSVtk transgene expression in human glioblastoma xenografts 
is sufficient for effective GCV activation. 
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Figure 27. Targeted molecular-genetic imaging of intracranial brain tumors. (A) 
Temporal dynamics of HSVtk gene expression as assessed by micro-PET imaging with 
[18F]-FEAU.  Significant HSVtk expression (*Student’s t test, p<0.05) 10 d after 
systemic administration was observed with CRTIGPSVC-AAVP compared to control 
insertless-AAVP. (B and C) Combined PET/CT images of brain tumor-bearing animals 
systemically administered with targeted CRTIGPSVC AAVP-HSVtk (B) or control 
insertless AAVP-HSVtk (C).  Axial, coronal, sagittal planes are shown. [18F]-FEAU 
uptake was observed only in animals receiving CRTIGPSVC-AAVP.  Arrows point to 
the tumor area.  R, right; L, left.   
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Figure 28. Tumor apoptosis by CRTIGPSVC-AAVP therapy.  Detection of apoptotic 
cells by TUNEL was performed on tumor tissue sections of animals treated with control 
insertless-AAVP (B) or with CRTIGPSVC-AAVP (C).  (A) Untreated animals received 
only vehicle.  (D) Non-immune IgG control.  Low magnification insets of serial tumor 
sections demonstrate the area containing the high-magnification views. 
 73 
In order to assess the feasibility of this strategy for clinical applications, we used 
high-throughput glioma TMA samples to analyze the expression of TfR in a large (n=165) 
and comprehensive panel of primary human gliomas with well-annotated clinical and 
pathological features from the UTMDACC brain tumor bank (Fig. 29A). We first noted that 
small blood vessels were positive for TfR in the normal brain, a result consistent with the 
targeting properties of the CRTIGPSVC-phage observed in normal mouse brain (Fig. 29B, 
arrows).  In GBM, the most common and aggressive primary brain tumor in humans, strong 
(3+) and moderate (2+) TfR staining was observed in tumor cells in 49 out of 56 (85%) 
analyzed samples (Fig. 30) (8, 115).  Similarly, we observed strong (3+) and moderate (2+) 
in 4 out of 8 cases of gliosarcomas (GS; n=8; Fig. 31A) and 9 out of 26 cases of anaplastic 
astrocytomas (AA; n=26; Fig. 31B).  In contrast, tumor cells were negative within the limits 
of our immunohistochemical procedures in low-grade oligodendrogliomas (O; n=28) (Fig. 
31C), anaplastic mixed oligoastrocytomas (AMOA; n=11; not shown), mixed 
oligoastrocytomas (MOA; n=10; not shown), and anaplastic oligodendrogliomas (AO; n=22; 
not shown) samples.  This patient-derived data set confirms that TfR is a suitable candidate 
target in GBM for translation into clinical applications and suggests potential expansion into 
other primary brain tumors.
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Figure 29. Transferrin receptor expression in comprehensive human glioma tissue 
microarrays.  (A) Glioma tissue microarray maps and H&E-stained tissue sections.  
Abbreviations: AA, anaplastic astrocytoma; AO, anaplastic oligodendroglioma; AMOA, 
anaplastic mixed oligoastrocytoma; GM, glioblastoma multiforme; GS, gliosarcoma; 
LGA, low-grade diffuse astrocytoma; MOA, mixed oligoastrocytoma; NB, normal brain; 
O, oligodendroglioma.  (B) Inset represents negative control. 
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Figure 30.  Transferrin receptor is highly expressed in glioblastoma.  Tissue samples 
from 56 different patients were immunohistochemcially stained for transferrin receptor 
and scored by a pathologist. Intense tumor cell (3+ or 2+) and vascular staining was 
noted in 49 of 56 samples.  Pathology score for tumor cells: 3+: strong; 2+: moderate; 
1+: weak.  Arrows point to blood vessels.  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Figure 31. Transferrin receptor is expressed in primary human CNS tumors.  
Transferrin receptor is highly expressed in gliosarcomas (A) and anaplastic astrocytomas 
(B), but tumor cell reactivity was low in oligodendrogliomas (C). Arrows point to blood 
vessels. 
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CHAPTER 4: DISCUSSION 
In summary, we show that a combinatorial phage display screening in vivo identified 
peptide ligands that localize to the brain following systemic administration.  One of the identified 
peptides, CRTIGPSVC, demonstrated robust and specific brain targeting in a molecular complex 
involving transferrin and transferrin receptor.  The peptide induced a partial conformational 
change in Tf, suggesting a similar but non-canonical iron-like interaction and a potential 
targeting mechanism.  In a model of human glioma, a combination of TfR overexpression plus 
extended vascular permeability and ligand retention resulted in effective tumor targeting.  
Further, analysis of patient-derived human primary brain tumor specimens supports the concept 
that the CRTIGPSVC peptide and the TfR system may serve as a translational approach for the 
detection and treatment of GBM and other gliomas.  
 In vivo phage display screenings have successfully identified a number of vascular 
targeting ligands specifically localizing to both normal organs and tissue from angiogenesis 
related diseases (112, 116).  The data support the physiological differences observed in capillary 
beds of various organs, in particular the endothelium of the brain, and predict that site-specific 
delivery exploiting molecular differences remains plausible.   One of the unique advantages of in 
vivo screenings lies in peptide selection under native conditions.  This functional screen 
identifies ligand-receptor interactions that are inherently accessible from the  systemic 
circulation and allow for multi-protein complex formations that may be overlooked in isolated-
protein or cell-based approaches.  Thus, one might speculate that, given the identified interaction 
between the CRTIGPSVC peptide and Tf with TfR, this unique interacting complex would not 
have been isolated in another experimental setting.  Moreover, to our knowledge, the induction 
of a conformational change in Tf similar to that of iron is unique to CRTIGPSVC and may not 
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have been functionally isolated in vitro.  Together, these data exemplify the biological relevance 
of in vivo screening assays and support the utility of in vivo phage display for vascular targeting 
approaches. 
Narrow therapeutic indices often limit the use and effectiveness of available treatments.  
The concept of targeted therapies suggests that traditionally cytotoxic agents could be 
specifically directed to diseased sites, allowing for increased local concentrations and limited 
systemic toxicity.  One of the most well-studied and intensely developed systems has centered on 
the Tf:TfR interaction, particularly as a cancer therapy strategy, due to high TfR expression on 
actively dividing cells, efficient receptor internalization, and cell surface receptor localization 
(44, 45).  Investigators have employed a number of strategies to exploit this system for delivery, 
including use of monoclonal antibodies against TfR, Tf fusion products, and Tf-directed viral 
and manufactured complexes, among others.  The novelty of the worked presented here lies in 
the use of a short peptide to mediate selective delivery rather than larger and bulkier antibodies, 
antibody fragments or Tf protein per se.  Further study of the binding affinity, avidity, and 
pharmacokinetics of CRTIGPSVC compared to current Tf-related agents will ultimately 
determine whether this peptide-mediated approach will yield clear and consistent results in 
patients. 
The precise structural details of iron binding to apo-Tf and the resultant 
conformational change induced by the binding event has been well studied.  X-ray 
crystallography coupled with site-directed mutagenesis demonstrated that eight tryptophan 
(Trp) residues are intimately involved in iron binding to apo-Tf (43).  Of note, a differential 
number of Trp residues are involved in binding to each lobe of apo-Tf, supporting the 
distinct association and dissociation profiles of iron with Tf.  Three Trp residues (Trp8, 
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Trp128 and Trp264) form a coordination complex within the N-lobe with iron whereas five 
Trp residues (Trp344, Trp358, Trp441, Trp460 and Trp550) coordinate iron binding in the 
C-lobe.  Given the intrinsic fluorescence characteristic of Trp, it was previously reported 
that assessment of changes in Trp fluorescence could be used to monitor iron-induced 
conformational changes in Tf (107-109).  We were able to use steady state fluorescence 
(SSF) and circular dichroism (CD) analysis to demonstrate CRTIGPSVC-induced 
conformational changes in Tf, akin to iron (Figs. 15 and 16).  However, as apo-Tf binds two 
iron (Fe3+) ions, SSF and CD were unable to readily distinguish peptide-binding 
characteristics to each lobe of Tf.  Similar studies could be performed with “locked” 
monoferric Tf molecules, such as use of a Tf with a point mutation of Arg 623 to alanine 
(TfR623A) to mimic the conformational change of iron binding to the C-lobe or a similar 
mutant mimicking an iron-bound N-lobe (TfK206E).  Such mutants in previous studies 
determined that the N-lobe is sensitive to C-lobe conformation and relatively insensitive to 
TfR or pH, whereas the C-lobe is most sensitive to the presence of TfR and changes in pH 
(117).  Thus, further analysis to elucidate the exact interacting lobe and binding residues will 
enhance understanding of the targeting dynamics of CRTIGPSVC and lead to future 
peptidomimetics with optimal binding characteristics. 
The CRTIGPSVC-phage significantly accumulated in the brain as early as 10 minutes 
after systemic administration compared to the insertless control.  Microvessel depletion analysis 
suggested that while the amount of phage retained within the vasculature for CRTIGPSVC-
phage and the insertless control was similar at 10 minutes, CRTIGPSVC-mediated crossing of 
the normal BBB contributed to the total binding profile observed (Fig. 9).  At 30 minutes, the 
data suggest that non-specific interactions with the brain endothelium are relatively cleared and 
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CRTIGPSVC-phage mediates specific binding to the cerebral blood vessels and crossing into the 
brain parenchyma.  Thus, this time-dependent clearance and retention act in a coordinated 
fashion to mediate specific targeting by the normal brain.  We have not yet systematically 
evaluated whether there is significant passage of AAVP or phage vectors from normal brain 
endothelial cells to parenchymal cells in the first min after administration.  Further study of the 
temporal dynamics of CRTIGPSVC-phage-mediated crossing of the BBB, and thereby TfR cell 
surface internalization and recycling, will be critical in future development of this ligand-
directed delivery system. 
 We observed an enhanced delivery efficiency of CRTIGPSVC-phage to human-derived 
intracranial brain tumors.  The robust targeting was supported by enhanced TfR expression 
within the tumor, a function of both increased endothelial cell expression and microvessel 
density within the tumor.  However, given the dynamics of CRTIGPSVC-mediated targeting, it 
remains likely that other parameters may ultimately influence tumor targeting, including 
circulation time, endothelial permeability, hydrostatic pressure, and receptor turnover rate.  It 
also stands to reason that these factors may contribute to differences in the delivery of 
CRTIGPSVC-AAVP to normal mouse brain versus the grafted human brain tumors, where 
receptor accessibility and distribution within the tumor vasculature are likely crucial elements 
directing specific targeting.  Of note, our studies utilized a single animal model of human 
glioblastoma, patient-derived U87-MG glioblastoma cells.  While the model recapitulates 
important characteristics of human disease, it does not infiltrate surrounding brain tissue, a key 
feature of human GBM.  It will be important to validate and extend pre-clinical study of 
CRTIGPSVC-mediated tumor targeting to additional models of intracranial brain tumors, 
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xenografts or transgenic models, to gain confidence for future success in translational 
applications.  
  Gene-directed enzyme prodrug therapy approaches, including suicide-gene therapy with 
HSVtk, afford the unique ability to non-invasively monitor delivery and transduction efficiencies, 
gene expression profiles over time, and efficacy of therapies with a single agent.  Two critical 
aspects to be addressed for successful application of this methodology are use of well-
characterized ligand-receptor pairs to drive specific localization and use of a gene delivery 
system enabling robust transgene expression.  AAVP integrates such specific targeting ligands 
with a mammalian gene delivery system that is potentially highly adaptable to any ligand-
receptor system through manipulation of the pIII targeting sequence.  We demonstrated 
CRTIGPSVC-targeted AAVP carrying HSVtk allowed for tumor visualization by PET/CT with 
the radiolabeled nucleoside [18F]-FEAU and therapy with GCV.  A single administration of 
CRTIGPSVC-AAVP-HSVtk and GCV treatment for 5 days resulted in a 50% decrease in tumor 
volume.  Further optimization of AAVP administration (single vs. multiple administrations) and 
GCV schedules could potentially improve tumor therapy and may aid in the development of 
clinical translation. 
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CHAPTER 5: SUMMARY AND SIGNIFICANCE 
Targeted delivery of agents from the circulation into intact CNS or into brain tumors 
thus appears to have great translational relevance. The design and validation of a clinic-
ready AAVP-based targeting trans-BBB approach may open the prospect of visualizing the 
presence of brain tumors and precise determination of location for diagnosis.  This could 
empower managing clinicians to serially quantify spatial changes in response to therapy in 
real-time.  Moreover, one might predict that either genetic disorders globally affecting the 
CNS (i.e., lysosomal storage and myelin diseases) or degenerative diseases targeted to 
specific neuronal populations would likely benefit from the attributes of the CRTIGPSVC 
peptide which, in principle, allows selective delivery of the agents without simultaneous 
opening of the BBB to potentially harmful blood-derived molecules.  The very property of 
selective opening of the BBB precludes assaying the efficiency of targeted AAVP delivery 
by the standard methods of measuring transfer of tracers from the blood into CNS 
parenchyma.  Finally, given our human TMA results, the translation of the functional 
features of peptide-directed particles from animal models into clinical applications may hold 
promise for the targeted molecular imaging and therapy of brain tumors in cancer patients.  
Further medical applications against other neurological disorders, especially those with high 
TfR concentrations may also be envisioned.  
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